gene therapy
Scottish borders-based Ryboquinn acquires viral delivery comany Nanogenics
July 20, 2018Medical Communications M&A, MA, Scotland, acquisitions, gene therapy, nanogenics, ryboquinn
The Scottish biotech company Ryboquinn has acquired English partner Nanogenics Solutions in a deal worth £4.45 million. The Selkirk-based firm …
Novartis CEO makes mark with $8.7bn AveXis acquisition
April 9, 2018Sales and Marketing AveXis, Novartis, biotech, drugs, gene therapy, pharma, pharmaceutical
Vas Narasimhan’s first few moves as CEO of Novartis indicate that he is not afraid to take bold risks in …
Spark gains approval for gene therapy, paving way for first $1m treatment
December 20, 2017Research and Development, Sales and Marketing Spark Therapeutics, biotech, drugs, gene therapy, pharma, pharmaceutical
The FDA handed approval to Spark Therapeutics’ gene therapy for an inherited eye disorder, making it the first treatment of …
Gene therapy helps child regrow 80% of skin
November 9, 2017Medical Communications, Research and Development biotech, drugs, gene therapy, pharma, pharmaceutical, stem cell
A young child has been brought back from the verge of death after an experimental combination of stem cell and …
Gene therapy: Advanced treatments for a new era
March 3, 2017Medical Communications gene therapy
Aranca discusses the considerable advances that have occured in the last few years in gene therapy.Considerable research has been conducted …
Pfizer expands gene therapy operations with acquisition of Bamboo Therapeutics
August 2, 2016Manufacturing and Production, Research and Development Pfizer, acquisition, bamboo therapeutics, gene therapy
Pfizer has announced that it has acquired gene therapy biotech Bamboo Therapeutics for an initial $150 million, with potential milestone …
Strong early data on haemophilia gene therapy boosts Biomarin
July 28, 2016Medical Communications, Research and Development BioMarin, gene therapy, haemophilia a
Biomarin has presented interim results from a Phase I/II study that is being hailed as positive “proof-of-concept” data for their …
GSK’s gene therapy Strimvelis gets European regulatory nod
June 1, 2016Research and Development, Sales and Marketing EU, European Commission, GlaxoSmithKline, Strimvelis, gene therapy, regulation
UK drugmaker GlaxoSmithKline (LSE: GSK) said its gene therapy Strimvelis has secured backing from the European regulators. The European Commission …
Pfizer and Spark Therapeutics present early data on bio-engineered haemophilia drug
May 23, 2016Research and Development, Sales and Marketing Pfizer, Spark Therapeutics, gene therapy, haemophilia B
Pfizer (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) have announced that they will present data showing encouraging signs in their …
Biogen signs $2 billion partnership deal with UPenn for gene therapies
May 17, 2016Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research
Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …
Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease
April 21, 2016Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease
Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
GSK’s gene therapy for rare condition in children gets EMA backing
April 4, 2016Research and Development, Sales and Marketing ADA-SCID, European Medicines Agency, GlaxoSmithKline, Orphan Therapy, Rare Treatment, drug trial, gene therapy
UK drug major GlaxoSmithKline (LSE: GSK) has won marketing recommendation from European regulators for its first gene therapy to treat …
Construction for new £55m cell and gene manufacturing centre in Stevenage begins
November 24, 2015Manufacturing and Production Catapult, Cell Therapy Catapult, Hertfordshire, gene therapy, manufacturing, stevenage
The Government-backed Cell Therapy Catapult has begun the construction for its cell and gene therapy manufacturing centre. The construction …
Vertex’s cystic fibrosis drug gets FDA approval
July 3, 2015Research and Development, Sales and Marketing FDA, Orkambi, Vertex, cystic fibrosis, gene therapy
Vertex Pharmaceuticals cystic-fibrosis drug Orkambi, which could treat as many as 8,500 patients in the US, has been approved by …
Sanofi makes gene therapy move
February 13, 2015Research and Development, Sales and Marketing Genzyme, Sanofi, Voyager Therapeutics, gene therapy, merger
Sanofi has signalled its intent to develop gene therapy treatments for nerve diseases through a $745 million deal with US …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
